⌘K
t
Graft Polymer (UK) Plc announced on 11 July 2024 the filing of two new provisional utility patent applications with the United States Patent and Trademark Office (USPTO) for the treatment of substance use disorders and mental health disorders using depot drug delivery systems. The company also provided an operational review update, referencing its 6 June 2024 announcement that the Board was evaluating a shortlist of five entities for potential commercial collaboration.
| Date | 11 Jul 2024 |
| Time | 07:00:08 |
| Category | Corporate updates |
| ID | 9513V |
11 July 2024
Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")
Filing of two new provisional patents applications in the US and operational review update
Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, is pleased to announce the filing of two new provisional utility patent applications with the United States Patent and Trademark Office (the "USPTO"). These provisional patent applications pertain to the treatment of substance use disorders ("SUDs") and mental health disorders using depot drug delivery systems ("DDDS").
Provisional patent applications
SUDs
The first provisional patent application, titled "Compositions and Methods for Treating Substance Use Disorders (SUDs) Using Depot Drug Delivery Systems (DDDS)", addresses the use of DDDS to reduce side effects and enhance effectiveness of therapeutics used to treat SUDs. Many such therapeutics require frequent dosing via traditional routes of administration, and controlling and extending drug release, such as using biopolymer based depot delivery systems, can potentially increase patient compliance and potentially improve outcomes.
Mental health disorders
The second provisional patent application, titled "Compositions and Methods for Treating Mental Health Disorders (MHDS) Using Depot Drug Delivery Systems (DDDS)", also focuses on the use of DDDS to reduce side effects and enhance effectiveness of therapeutics, in particular those used in treating mental health disorders such as Generalized Anxiety Disorder ("GAD"), Major Depressive Disorder ("MDD") and Post-Traumatic Stress Disorder ("PTSD"). Similar to treatments for SUDs, current formulations of these therapeutics often are limited in their effectiveness and have increased side effects as a result of gastric and hepatic degradation of the API, drawbacks which are eliminated by the use of biopolymer based depot delivery systems, such as for controlled subcutaneous release.
Strategic significance
These patent applications aim to leverage the Company's biopolymer expertise to address significant unmet medical needs in addiction and mental health therapy, particularly in the US market. They represents continued progress in developing the Company's intellectual property ("IP") portfolio. They also signify further progress in the Company's strategic focus on the healthcare industry, following the disposal of its industrial plastic manufacturing unit, Graft Polymer D.O.O. (which was announced on 3 May 2024), and the successful completion of the Company's recent fundraise
Operational review update
On 6 June 2024, the Company announced an update on the progress of its operational review, disclosing that the Board was evaluating a shortlist of five entities for potential future commercial collaboration in the Company's area of operation. This operational review is nearing completion and the Company looks forward to providing further details in the near term.
Anthony Tennyson, CEO, commented: "We are pleased to announce the filing of these two new provisional patent applications, which marks another step forward in our work to leverage the Company's biopolymer expertise for the potential treatment of substance abuse and mental health disorders. Our strategic focus on healthcare, underscored by these applications and our recent corporate actions, demonstrates our commitment to innovation and growth in this vital sector."
Enquiries
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director, Email: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive Director , Email: yifat@graftpolymer.com
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner (Corporate Finance)
Guy McDougall (Sales)
+44 (0) 20 3328 5656
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc (LON: GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system ("SNEDDS"), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients ("APIs") into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.